Zentalis Pharmaceuticals, Inc. (ZNTL) company profile
Close on Nov 18, 2026Market cap $97.47MP/E –Yield –
About Zentalis Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted cancer therapies. Its lead product candidate is azenosertib, an investigational, orally administered small-molecule WEE1 inhibitor designed to selectively halt DNA damage repair in tumor cells and induce cell death. The firm concentrates its clinical development efforts on oncology indications, particularly platinum-resistant ovarian cancer characterized by Cyclin E1 overexpression, while exploring applications in other solid tumors. Its target patient populations include individuals diagnosed with advanced ovarian malignancies and other solid tumors who have received prior therapies.
The enterprise conducts its clinical development and intellectual property activities internationally, holding patents and trademark registrations in jurisdictions including the United States, the United Kingdom, the European Union, Japan, and China. It operates without internal manufacturing facilities and relies entirely on independent contract manufacturing organizations to produce, package, and distribute its investigational drug candidates. The provided text does not state the location of the company's headquarters.
Summary of the business section of Zentalis Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zentalis Pharmaceuticals, Inc.
- Headquarters
- San Diego, CA
- Address
- 10275 Science Center Drive, Suite 200 92121
- Phone
- (858) 263-4333
- Website
- zentalis.com
- Employees
- 106, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, San Diego, California
Stock & identifiers
- Ticker
- ZNTL
- Exchange
- Nasdaq
- IPO date
- Apr 6, 2020
- Shares outstanding
- 72M, Aug 3, 2026
- Public float
- $66.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1725160
- CUSIP
- 98943L107
- ISIN
- US98943L1070
- FIGI
- BBG00R2K8TF5
- Share class FIGI
- BBG00R2K8TG4
- EIN
- 82-3607803
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Julia Marie Eastland | CEO & President, Director | 79,133 |
| Ingmar Bruns | Chief Medical Officer | 43,059 |
| Vincent Vultaggio | PAO and PFO | 146,506 |
| James B. Bucher | Chief Legal Officer | – |
| Mark Lackner | Chief Scientific Officer | 512,856 |
| Andrea Paul | Chief Legal Officer | 1,070,784 |
| Enoch Kariuki | Director | 194,465 |
| Jan Skvarka | Director | 264,254 |
| Luke Nathaniel Walker | Director | 201,384 |
| Scott Dunseth Myers | Director | 395,895 |
| David Michael Johnson | Director | 307,521 |
| Shannon Campbell | Director | 114,200 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.30M | -$2.42M | $1.44M | $7 | – |
| FY2024 Blackwell | $7.47M | -$24.58M | $5.34M | $15 | – |
| FY2024 Eastland | $8.19M | $5.92M | $5.34M | $15 | – |
| FY2024 Julie Eastland | – | -$619.34K | $5.34M | $15 | – |
| FY2023 Blackwell | $12.85M | $6.59M | $5.58M | $75 | – |
| FY2023 Julie Eastland | – | $3.03M | $5.58M | $75 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Julie Eastland President and Chief Executive Officer | $700.00K | – | $99.77K | $56.98K | $441.00K | $2.98K | $1.30M | -84% |
| Ingmar Bruns, M.D. Chief Medical Officer | $530.00K | – | $27.94K | $15.95K | $278.25K | $17.70K | $869.84K | – |
| James Bucher Chief Legal Officer and Corporate Secretary | $144.23K | $50.00K | – | $391.75K | $67.32K | $6.68K | $659.97K | – |
| Andrea Paul Former Chief Legal Officer and Corporate Secretary | $376.92K | – | $2.22M | $101.15K | – | $294.75K | $2.99M | -19% |
| Mark Lackner, Ph.D. Former Chief Scientific Officer | $153.55K | – | $547.60K | $64.81K | – | $463.39K | $1.23M | -74% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 6, 2020
- Offer price
- $18.00
- Securities offered
- 9,180,000
- Gross proceeds
- $165.24M
- Exchange
- Nasdaq
- First trading day
- Apr 3, 2020
- First-day close
- $23.20+28.9%
- Lock-up ends (est.)
- Sep 30, 2020
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Zentalis had a total of 106 employees all of whom were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 25, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 24, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 6, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 6, 2020 | Name change | Name changed from Zentalis Pharmaceuticals, LLC to Zentalis Pharmaceuticals, Inc. |
| Apr 2, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 5, 2019 | Name change | Name changed from Zeno Pharma, LLC to Zentalis Pharmaceuticals, LLC |
See a number that looks wrong?